Supplementary table 1. Indicative power							
Sample Size	Power	Number without RVD	Number with RVD	Mortality in patients without RVD	Mortality in patients with RVD	Odds Ratio	
120	80%	60	60	0.373	0.627	2.83	
120	90%	60	60	0.354	0.646	3.33	
150	80%	75	75	0.386	0.614	2.53	
150	90%	75	75	0.369	0.631	2.92	
120	80%	90	30	0.427	0.719	3.43	
120	90%	90	30	0.417	0.749	4.17	
150	80%	112	38	0.435	0.695	2.96	
150	90%	112	38	0.426	0.722	3.50	

Differences in mortality rates that could be detected at a 5% significance level for sample sizes of 120 and 150, and proportions of patients with RV dysfunction of 25% and 50%, assuming an overall mortality rate of 50%. RVD = Right Ventricular Dysfunction.

Supplementary Table 2. Determination of primary outcome							
RV dilatation	Septal flattening	Primary outcome	Included/excluded	n			
Yes	Yes	Yes	Included	7			
Yes	Unable to assess	Unknown	Excluded	0			
Yes	No	No	Included	24			
Unable to assess	No	No	Included	2			
No	No	No	Included	74			
No	Yes	No	Included	2			
No	Unable to assess	No	Included	3			
Unable to assess	Unable to assess	Unknown	Excluded	6			
RV = Right Ventricle							

Supplementary Ta	ble 3. Patient characteristics a	t ICU admission			
		All	RVD	No RVD	
		(n=112)	(n=33)	(n=79)	p-value
Age, years		59.2 (11.3)	60.7 (9.9)	58.5 (11.8)	0.326#
Sex, Male		74 (66.1%)	22 (66.7%)	52 (65.8%)	>0.99†
BMI, kg m-2	n (n missing)	110(2)	32 (1)	78 (1)	
		32.9 (7.1)	32.9 (6.7)	32.8 (7.3)	0.952#
Ethnicity	White	100 (89.3%)	26 (78.8%)	74 (93.7%)	0.039^{\dagger}
	Non-white	12 (10.7%)	7 (21.2%)	5 (6.3%)	0.037
Time since sym days	ptom onset to intubation,	11 [7, 16]	11.0 [7, 17]	10.5 [7.2, 14]	0.384‡
Clinical frailty	score n (n missing)	111 (1)	33 (0)	78 (1)	
•		2.4 (0.9)	2.4(1)	2.3 (0.9)	$0.930^{\#}$
APACHE II	n (n missing)	107 (5)	33 (0)	74 (5)	
		16.6 (5.8)	16.8 (5.1)	16.6 (6.2)	0.877#
CCCC	n (n missing)	102 (10)	29 (4)	73 (6)	
		10.2 (2.7)	10.8 (1.9)	10.0(3)	0.105#
Comorbidities					
Smoking	Non-smoker	63 (56.2%)	22 (66.7%)	41 (51.9%)	
	Ex-smoker > 1 year	40 (35.7%)	10 (30.3%)	30 (38%)	0.293^{\dagger}
	Current or within 1 year	9 (8%)	1 (3%)	8 (10.1%)	
Alcohol	n (n missing)	110(2)	33 (0)	77 (2)	
history	None	34 (30.9%)	10 (30.3%)	24 (31.2%)	
	Minimal	57 (51.8%)	20 (60.6%)	37 (48.1%)	0.544^{\dagger}
	Moderate	8 (7.3%)	1 (3%)	7 (9.1%)	
	Excess	11 (10%)	2 (6.1%)	9 (11.7%)	
Hypertension		38 (33.9%)	13 (39.4%)	25 (31.6%)	0.513^{\dagger}
Coronary arter	y disease	11 (9.8%)	4 (12.1%)	7 (8.9%)	0.333 [†]
Diabetes		33 (29.5%)	9 (27.3%)	24 (30.4%)	0.823^{\dagger}
Asthma		16 (14.3%)	4 (12.1%)	12 (15.2%)	0.775^{\dagger}
COPD		10 (8.9%)	2 (6.1%)	8 (10.1%)	0.803^{\dagger}
Treatments before i	ntubation				
Intravenous co	rticosteroids	74 (66.1%)	25 (75.8%)	49 (62%)	0.193^{\dagger}
Non-invasive vo	entilation	76 (67.9%)	22 (66.7%)	54 (68.4%)	>0.99†
High flow nasal	l oxygen	65 (58%)	24 (72.7%)	41 (51.9%)	0.058^{\dagger}
Awake self-proning		57 (50.9%)	19 (57.6%)	38 (48.1%)	0.411†
Acute comorbidities	s since hospital admission				
New arrhythmi		17 (15.2%)	6 (18.2%)	11 (13.9%)	0.573 [†]
Confirmed or	Radiologically confirmed	4 (3.6%)	4 (12.1%)	0 (0%)	
	Clinically suspected	5 (4.5%)	2 (6.1%)	3 (3.8%)	0.010^{\dagger}
suspected PTE	No	101 (90.2%)	27 (81.8%)	74 (93.7%)	0.010
rie	Unknown	2 (1.8%)	0 (0%)	2 (2.5%)	
ACS		5 (4.5%)	2 (6.1%)	3 (3.8%)	0.630 [†]
Requirement fo	or RRT	18 (16.1%)	6 (18.2%)	12 (15.2%)	0.779 [†]

RVD defined as RV dilatation and/or septal flattening

RVD = Right Ventricular Dysfunction, BMI = Body Mass Index, APACHE = Acute Physiology And Chronic Health Evaluation, CCCC = Coronavirus Clinical Characterisation Consortium, COPD = Chronic Obstructive Pulmonary Disease, PTE = Pulmonary Thromboembolism, ACS = Acute Coronary Syndrome, RRT = Renal Replacement Therapy.

Supplementary Table 4. Clinical consequences				
	All	RVD	No RVD	p-value
30-day follow-up	(n=112)	(n=33)	(n=79)	
Death	53 (47.3%)	17 (51.5%)	36 (45.6%)	0.679 [†]
RRT	28 (25%)	9 (27.3%)	19 (24.1%)	0.879 [†]
Prone ventilation	55 (49.1%)	13 (39.4%)	42 (53.2%)	0.213 [†]
Referral for ECMO	15 (13.4%)	1 (3.0%)	14 (17.7%)	0.097^{\dagger}

RVD defined as RV dilatation and/or septal flattening Data are presented as n (%). Data are complete unless indicated by n (n missing). P-values provided are for comparisons between RVD vs no RVD. \dagger = Fisher's Exact test.

RRT = Renal Replacement Therapy, ECMO = Extra Corporeal Membrane Oxygenation.

Supplementary Table 5. Patier		All	RVD	No RVD	
		(n=112)	(n=33)	(n=79)	p-value
Requirement for prone inv	vasive ventilation	79 (70.5%)	28 (84.8%)	51 (64.6%)	0.061†
since ICU admission					
SOFA score		7.9 (3)	8.8 (3.2)	7.6 (2.8)	0.048#
Requirement for RRT on o	day of echo	15 (13.4%)	7 (21.2%)	8 (10.1%)	0.135 [†]
Lab Measurements					
Arterial Blood Gas					
[H ⁺], nmol L ⁻¹	n (n missing)	97 (15)	29 (4)	68 (11)	
		39 [35.8, 46]	40.9 [36, 49]	39 [34.8, 45]	0.230‡
PaO ₂ , kPa		9.3 (1.2)	9.1 (1.3)	9.4 (1.2)	0.428#
PaCO ₂ , kPa	n (n missing)	109 (3)	33 (0)	76 (3)	0.020*
DE 1		6.9 [5.9, 8]	7.0 [5.9, 7.9]	6.8 [5.9, 8]	0.929‡
BE, mmol	n (n missing)	110(2)	33 (0)	77 (2)	0.026#
Bicarbonate, mmol L ⁻¹	n (n missins)	5.9 (6.5) 109 (3)	3.8 (6.4)	6.8 (6.3)	0.026#
Bicardonate, mmoi L	n (n missing)		33 (0)	76 (3)	0.063#
Full Blood Count		31.8 (6.6)	30.0 (6.1)	32.5 (6.7)	0.005
Haemoglobin, g dl ⁻¹		11 (1.8)	10.7 (1.4)	11.2 (1.0)	0.127#
Neutrophils, x10 ⁹ L ⁻¹		10.5 [8.5, 14.9]	12.3 [8.9, 17.7]	11.2 (1.9) 10.3 [8.4, 13.6]	0.127**
Lymphocytes, x10° L°1		0.9 [0.5, 1.4]	0.9 [0.7, 1.5]	0.9 [0.4, 1.3]	0.128*
Platelets, x10 ⁹ L ⁻¹		279.5 (109.5)	276.5 (105.7)	280.8 (111.7)	0.239*
Inflammation		413.3 (103.3)	410.5 (105.1)	200.0 (111./)	0.849"
CRP, mg L ⁻¹		61.5 [11.8, 157.5]	72.0 [14, 178]	54.0 [11, 149]	0.375‡
Coagulation		01.3 [11.0, 137.3]	14.0 [14, 1/6]	J4.0 [11, 149]	0.373*
D-Dimers, mg L ⁻¹ FEU	n (n missing)	81 (31)	27 (6)	54 (25)	
D-Dinicis, ing L - FEU	n (n missing)	,	27 (6) 1156 [504,	34 (23) 1373 [724.8,	
		1264 [601, 2605]	2822]	2496]	0.745‡
PT, seconds		12 [11, 13.2]	13 [11, 13]	12 [11, 13.2]	0.264‡
APTT, seconds	n (n missing)	111 (1)	33 (0)	78 (1)	0.204
111 11, 50001105	iv (iv mussing)	27 [25, 31]	29 [26, 31]	26 [24, 30]	0.031‡
Electrolytes		[==, -,]	[-0, 02]	<u> ', </u>	
Creatinine, µmol L ⁻¹		69.5 [53.5, 107]	84 [54, 118]	64 [53, 99]	0.099‡
Cardiac biomarkers		. ,1	. , .,	. , .	
NT-proBNP, ng L ⁻¹	n (n missing)	100 (12)]	32 (1)	68 (11)	
2 / 5	. 3/	458 [198.5,	537.5 [208,	430.5 [194,	0.213‡
		1689.5]	3634.2]	1275.2]	U.215*
Abnormal NT-proBNP ^A	n (n missing)	100 (12)	32 (1)	68 (11)	
		63 (63%)	20 (62.5%)	43 (63.2%)	>0.99†
hsTn I, ng L ⁻¹	n (n missing)	64 (48)	24 (9)	40 (39)	
		12[4.8, 42]	19.5 [4.8, 42]	10.0 [4.8, 40]	0.605‡
hsTn T, ng L ⁻¹	n (n missing)	46 (66)	9 (24)	37 (42)	
		16.5 [10, 28.5]	18 [15, 37]	16 [10, 26]	0.239‡
Abnormal troponin ^B	n (n missing)	110 (2)	33 (0)	77 (2)	0 ==='
		51 (46.4%)	17 (51.5%)	34 (44.2%)	0.535 [†]
Clinical Parameters		70 (10 C)	01.2 (21.1)	70.1 (10.7)	0.4.54
HR, bpm	a.	79 (19.9)	81.3 (21.1)	78.1 (19.5)	0.446#
Rhythm	Sinus	107 (95.5%)	31 (93.9%)	76 (96.2%)	0.620*
Maan DD	AF/Flutter	5 (4.5%)	2 (6.1%)	3 (3.8%)	0.630 [†]
Mean BP, mmHg	n (n missing)	109 (3)	32 (1)	77 (2)	0.089#
	n (nia-i)	80.9 (13.4)	77.9 (10.5) 22 (11)	82.1 (14.3) 52 (27)	0.089**
$CVD_{om}U_{\bullet}O$	n (n missing)	74 (38)	7.5 [6.0, 13.8]	52 (27) 7.0 [3.8, 11.2]	0.307*
CVP, cmH ₂ O	, 0,		7.5 [0.0, 13.6]	1.0 [3.0, 11.2]	
		7 [4, 12]			
Drug Administration			18 (54 5%)	22 (27 80%)	0.0104
Drug Administration Vasopressors		40 (35.7%)	18 (54.5%)	22 (27.8%)	0.010†
Drug Administration Vasopressors Inotropes		40 (35.7%) 1 (0.9%)	1 (3%)	0 (0%)	0.010† 0.295†
Drug Administration Vasopressors	Prophylactic	40 (35.7%) 1 (0.9%) 93 (83%)	1 (3%) 24 (72.7%)	0 (0%) 69 (87.3%)	0.295†
Drug Administration Vasopressors Inotropes	Prophylactic Therapeutic	40 (35.7%) 1 (0.9%) 93 (83%) 17 (15.2%)	1 (3%) 24 (72.7%) 9 (27.3%)	0 (0%) 69 (87.3%) 8 (10.1%)	
Drug Administration Vasopressors Inotropes Anticoagulation	Prophylactic	40 (35.7%) 1 (0.9%) 93 (83%) 17 (15.2%) 2 (1.8%)	1 (3%) 24 (72.7%) 9 (27.3%) 0 (0%)	0 (0%) 69 (87.3%) 8 (10.1%) 0 (0%)	0.295 [†] 0.057 [†]
Drug Administration Vasopressors Inotropes Anticoagulation Paralysis	Prophylactic Therapeutic	40 (35.7%) 1 (0.9%) 93 (83%) 17 (15.2%)	1 (3%) 24 (72.7%) 9 (27.3%)	0 (0%) 69 (87.3%) 8 (10.1%)	0.295†
Drug Administration Vasopressors Inotropes Anticoagulation Paralysis Ventilation	Prophylactic Therapeutic	40 (35.7%) 1 (0.9%) 93 (83%) 17 (15.2%) 2 (1.8%) 52 (46.4%)	1 (3%) 24 (72.7%) 9 (27.3%) 0 (0%) 18 (54.5%)	0 (0%) 69 (87.3%) 8 (10.1%) 0 (0%) 34 (43%)	0.295 [†] 0.057 [†] 0.511 [†]
Drug Administration Vasopressors Inotropes Anticoagulation Paralysis	Prophylactic Therapeutic None	40 (35.7%) 1 (0.9%) 93 (83%) 17 (15.2%) 2 (1.8%)	1 (3%) 24 (72.7%) 9 (27.3%) 0 (0%)	0 (0%) 69 (87.3%) 8 (10.1%) 0 (0%)	0.295 [†] 0.057 [†]

Plateau pressure, cmH ₂ O		58 (54)	19 (14)	39 (40)	
		24 [22, 27]	27 [25, 29.5]	24 [22, 26]	0.018^{\ddagger}
PAP, cmH ₂ O	n (n missing)	58 (54)	33 (0)	76 (3)	
		25 [20, 30]	27 [21, 30]	24 [20, 28.2]	0.176^{\ddagger}
Tidal volume, ml kg ⁻¹	n (n missing)	108 (4)	32 (1)	76 (3)	
(PBW)		7.2 (2.1)	7.2 (2.5)	7.2(2)	$0.964^{\#}$
P/F ratio		17 [13.6, 21.3]	15.2 [11.7, 18]	17.8 [14.3, 21.4]	0.047‡
PEEP, cmH ₂ O	n (n missing)	111 (1)	33 (0)	78 (1)	
		9.8 (3.6)	10.2 (3.4)	9.7 (3.7)	$0.447^{\#}$
Resp rate, minute ⁻¹		24.3 (5.3)	24.8 (5.2)	24.1 (5.3)	0.489#
Driving pressure, cmH ₂ O	n (n missing)	58 (54)	19 (14)	39 (40)	
		14.7 (7.1)	15.9 (5.7)	14.0 (7.6)	$0.290^{\#}$
Dynamic compliance, ml	n (n missing)	58 (54)	19 (14)	39 (40)	
cmH ₂ O ⁻¹		29.8 [20, 40]	21.3 [17.9, 36]	34.3 [22.7, 41.8]	0.082^{\ddagger}
Murray lung injury score	n (n missing)	100 (12)	31 (2)	69 (10)	
		2.8 [2.3, 3]	2.8 [2.5, 3.3]	2.8 [2.3, 3]	0.491^{\ddagger}

RVD defined as RV dilatation and/or septal flattening

Data are presented as mean (SD), median [IQR] or n (%). Data are complete unless indicated by n (n missing). P-values provided are for comparisons between RVD vs no RVD. # =Student's T-test. $\dag =$ Fisher's Exact test. # =Fisher's Exact test. # =Fisher's Exact test.

A, NT-proBNP ≥300 ng L⁻¹

B, $hsTnT \ge 15$ ng L^{-1} or $hsTnI \ge 34$ ng L^{-1} for males; ≥ 16 ng L^{-1} for females

RVD = Right Ventricular Dysfunction, RRT = Renal Replacement Therapy, BE = Base Excess, CRP = C-Reactive Protein, PT = Prothrombin Time, APTT = Activated Partial Thromboplastin Time, NT-proBNP = N-terminal pro B-type Natriuretic Peptide, hsTn = High Sensitivity Troponin, HR = Heart Rate, AF = Atrial Fibrillation, BP = Blood Pressure, CVP = Central Venous Pressure, FiO₂ = Fraction of Inspired Oxygen, PAP = Peak Airway Pressure, PBW = Predicted Body Weight, PEEP = Positive End Expiratory Pressure.

Supplementary Table 6. Logistic regression model predicting 30-day mortality adjusting for remaining variables in table

	OR (95% CI)	p-value
RV dilatation and/or septal flattening	1.35 (0.54, 3.46),	=0.523
Age, in years (per 5-year increase)	1.52 (1.21, 1.97),	=0.001
Female Gender	1.09 (0.44, 2.70),	=0.855
Non-white ethnicity	0.68 (0.15, 2.90),	=0.610
APACHE II score on admission to ICU (per 5-score increase)	1.30 (0.88, 1.98),	=0.191
Time from intubation to date of echo, in days (per 1-day increase)	1.02 (0.88, 1.17),	=0.826
APACHE = Acute Physiology And Chronic Health Evaluation		